The effects of the chelators on cellular proliferation of neoplastic and normal cells
| Chelator . | Neoplastic cells . | Normal cells . | ||||||
|---|---|---|---|---|---|---|---|---|
| SK-N-MC neuroepithelioma . | K562 eythroleukemia . | SK-Mel-28 melanoma . | MCF-7 breast cancer . | MRC-5 fibroblasts . | L8 rat skeletal muscle . | Human umbilical vein endothelial cells . | Human monocyte–derived macrophages . | |
| DFO | 22 ± 8 | > 25 | 7.5 ± 1.3 | > 25 | > 25 | > 25 | > 25 | > 25 |
| 311 | 0.3 ± 0.1 | 0.5 ± 0.1 | 0.8 ± 0.4 | 0.9 ± 0.3 | > 25 | 7.2 ± 1.8 | 5.4 ± 0.7 | 20.1 |
| 311m | 0.3 ± 0.1 | 0.6 ± 0.2 | 2.1 ± 0.1 | 1.2 ± 0.2 | > 25 | 9.9 ± 1.4 | 4.6 ± 0.2 | 21.6 |
| ST | > 12.5 | —* | — | — | — | — | — | — |
| NT | 0.5 ± 0.1 | 6.6 ± 1.9 | 9.6 ± 2.0 | 11.6 ± 0.8 | > 25 | > 25 | 4.5 ± 0.7 | 24.0 |
| N2mT | > 12.5 | — | — | — | > 25 | > 25 | 8.6 ± 4.6 | > 25 |
| N4mT | 0.5 ± 0.1 | 5.2 ± 1.5 | 11.6 ± 0.8 | 14.4 ± 3.1 | > 25 | > 25 | > 25 | > 25 |
| N44mT | 1.5 ± 0.2 | 1.8 ± 0.3 | 2.9 ± 1.6 | 5.9 ± 0.1 | > 25 | 9.8 ± 1.8 | 9.4 ± 0.4 | > 25 |
| N4eT | 1.6 ± 0.9 | — | — | — | — | — | — | — |
| N4aT | 2.3 ± 1.4 | — | — | — | — | — | — | — |
| N4pT | 3.3 ± 0.4 | — | — | — | — | — | — | — |
| N44pH | 5.2 ± 0.6 | — | — | — | — | — | — | — |
| NoctH | 10.5 ± 1.4 | — | — | — | — | — | — | — |
| FeNT | > 12.5 | — | — | — | — | — | — | — |
| Chelator . | Neoplastic cells . | Normal cells . | ||||||
|---|---|---|---|---|---|---|---|---|
| SK-N-MC neuroepithelioma . | K562 eythroleukemia . | SK-Mel-28 melanoma . | MCF-7 breast cancer . | MRC-5 fibroblasts . | L8 rat skeletal muscle . | Human umbilical vein endothelial cells . | Human monocyte–derived macrophages . | |
| DFO | 22 ± 8 | > 25 | 7.5 ± 1.3 | > 25 | > 25 | > 25 | > 25 | > 25 |
| 311 | 0.3 ± 0.1 | 0.5 ± 0.1 | 0.8 ± 0.4 | 0.9 ± 0.3 | > 25 | 7.2 ± 1.8 | 5.4 ± 0.7 | 20.1 |
| 311m | 0.3 ± 0.1 | 0.6 ± 0.2 | 2.1 ± 0.1 | 1.2 ± 0.2 | > 25 | 9.9 ± 1.4 | 4.6 ± 0.2 | 21.6 |
| ST | > 12.5 | —* | — | — | — | — | — | — |
| NT | 0.5 ± 0.1 | 6.6 ± 1.9 | 9.6 ± 2.0 | 11.6 ± 0.8 | > 25 | > 25 | 4.5 ± 0.7 | 24.0 |
| N2mT | > 12.5 | — | — | — | > 25 | > 25 | 8.6 ± 4.6 | > 25 |
| N4mT | 0.5 ± 0.1 | 5.2 ± 1.5 | 11.6 ± 0.8 | 14.4 ± 3.1 | > 25 | > 25 | > 25 | > 25 |
| N44mT | 1.5 ± 0.2 | 1.8 ± 0.3 | 2.9 ± 1.6 | 5.9 ± 0.1 | > 25 | 9.8 ± 1.8 | 9.4 ± 0.4 | > 25 |
| N4eT | 1.6 ± 0.9 | — | — | — | — | — | — | — |
| N4aT | 2.3 ± 1.4 | — | — | — | — | — | — | — |
| N4pT | 3.3 ± 0.4 | — | — | — | — | — | — | — |
| N44pH | 5.2 ± 0.6 | — | — | — | — | — | — | — |
| NoctH | 10.5 ± 1.4 | — | — | — | — | — | — | — |
| FeNT | > 12.5 | — | — | — | — | — | — | — |
The chelators and the iron complex of NT were incubated with cells for 72 hours. At the end of this incubation period, cell density was determined by the MTT assay as described in “Materials and methods” and presented as 50% inhibitory concentration (IC50) in μM.
Results are mean ± SD (3 experiments), except for human monocyte–derived macrophages (mean of 2 experiments).
DFO indicates desferrioxamine; other abbreviations are explained in the legend of Figure 1.
Dashes indicate data not determined.